Gene Modification Company Transposagen Receives $4.3M in Grants, Investments | GenomeWeb

NEW YORK (GenomeWeb News) – Gene modification firm Transposagen Biopharmaceuticals said on Friday that it received $4.3 million in grants and investments to further develop its DNA modification technology.

The Lexington, Ky.-based firm said that it received a Small Business Innovation Research grant of almost $2.0 million from the National Institutes of Health's Office of the Director, and a $1.0 million grant from the Kentucky Cabinet for Economic Development.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.